Palisade Bio, Inc. (PALI)
| Market Cap | 326.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.78M |
| Shares Out | 167.42M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,762,810 |
| Open | 1.960 |
| Previous Close | 1.960 |
| Day's Range | 1.940 - 2.050 |
| 52-Week Range | 0.530 - 2.855 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 11.29 (+478.97%) |
| Earnings Date | May 11, 2026 |
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and co... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for PALI stock is "Strong Buy." The 12-month stock price target is $11.29, which is an increase of 478.97% from the latest price.
News
Palisade Bio Transcript: 25th Annual Needham Virtual Healthcare Conference
A novel oral PDE4 inhibitor prodrug for IBD showed strong early efficacy and safety in UC and Crohn's, with 100% response in a UC phase Ib and robust PK/PD in Crohn's. Phase II trials are set for 2024, supported by $135M in cash and a precision medicine approach.
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biop...
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Compa...
Palisade Bio Transcript: Study result
Phase I-B data for PALI-2108 in fibrostenotic Crohn's disease showed strong safety, robust PK/PD, and early clinical activity, with 40% endoscopic response/remission in a refractory population. Once-daily oral dosing and dual anti-inflammatory/anti-fibrotic action support further development in broader Crohn's cohorts.
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic improvement...
Palisade Bio Transcript: TD Cowen 46th Annual Health Care Conference
PALI-2108, a locally activated PDE4 inhibitor prodrug, is advancing in IBD with strong early efficacy and safety data, a dual anti-inflammatory/anti-fibrotic mechanism, and a robust financial runway. Key clinical milestones are set for 2024–2028, with strategic flexibility in Crohn's indications.
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, ora...
Palisade Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company has restructured around a novel, gut-restricted PDE4 inhibitor with promising early clinical results in UC and FSCD. With strong financial backing and a clear development timeline, it is positioned for expansion into broader GI and potential non-GI indications.
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“...
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Virtual presentation scheduled for Thursday, February 26 th at 12:40 PM ET Access the webcast here Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the ...
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis
Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibroste...
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
PALI-2108 is the first and only PDE4 inhibitor in development targeting the terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) to address signif...
Palisade Bio Transcript: Piper Sandler 37th Annual Healthcare Conference
Upcoming milestones include early 2025 data from a Phase 1b Crohn's study and a definitive Phase II UC trial, both supported by strong fundraising. The lead PDE4 inhibitor shows rapid, potent efficacy with a favorable safety profile, targeting high unmet needs in IBD.
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
Live webcast fireside chat on Thursday, December 4 th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage b...
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical nee...
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutic...
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
Offering was led by B Group Capital and Columbia Threadneedle Investments with significant participation from Adage Capital Partners LP, ADAR1 Capital Management, Boxer Capital Management, Coastlands ...
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
Carlsbad, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel t...